Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (81)

2024

  1. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis

    Frontiers in Immunology, Vol. 15

2023

  1. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management

    International Journal of Dermatology, Vol. 62, Núm. 8, pp. 1020-1025

  2. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  3. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

  4. Supportive oncodermatology practices in Europe and the USA

    Journal of the European Academy of Dermatology and Venereology

  5. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

    Future oncology (London, England), Vol. 19, Núm. 35, pp. 2349-2359

2022

  1. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  2. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

    Journal of the European Academy of Dermatology and Venereology, Vol. 36, Núm. 3, pp. 332-350

  3. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

    Cancers, Vol. 14, Núm. 20

  4. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review

    Breast Cancer Research and Treatment, Vol. 194, Núm. 1, pp. 1-11

  5. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 29, pp. 3365-3376

  6. Shared decision making for patients with breast and gynecologic malignancies undergoing chemotherapy associated with persistent alopecia

    Gynecologic Oncology Reports, Vol. 44

  7. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

    JAMA Oncology, Vol. 8, Núm. 7, pp. 1047-1052

2021

  1. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156

  2. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495

  3. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  4. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

    Annals of Oncology, Vol. 32, Núm. 2, pp. 197-207

  5. Sacituzumab govitecan in metastatic triple-negative breast cancer

    New England Journal of Medicine, Vol. 384, Núm. 16, pp. 1529-1541

  6. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649